TABLE 7Main ongoing and planned phase 2/3/4 TB therapeutic clinical trials Trial Phase Control arm Country Experimental treatment regimen(s) Experimental treatment duration, months Notes ClinicalTrials.gov identifier Rifampicin-susceptible TB Beijing Chest Hospital 4 Yes China Isoniazid, rifampicin, pyrazinamide, ethambutol, and levofloxacin for the full course or isoniazid, rifampicin, pyrazinamide, and ethambutol for the full course 4.5 NCT02901288 CLO-Fast (ACTG 5362) 2 Yes Multicountry Clofazimine, ethambutol, isoniazid, pyrazinamide, and rifapentine for 8 weeks, followed by clofazimine, isoniazid, pyrazinamide, and rifapentine for 8 weeks 3 NCT04311502 Hi-DoRi-3 3 Yes South Korea Isoniazid, rifampicin 30 mg·kg −1 ,and pyrazinamide 3 months after culture conversion Treatment duration based on sputum culture conversion NCT04485156 OptiRiMoxTB 3 Yes Multicountry Ethambutol, isoniazid, pyrazinamide, and rifampicin 35 mg·kg −1 ,or isoniazid, moxifloxacin, pyrazinamide, and rifampicin 35 mg·kg−1 4 NCT05575518 ORIENT 3 Yes China Isoniazid, moxifloxacin, and pyrazinamide, plus: rifapentine 600 mg·day− 1 ,or rifapentine 1200 mg·day− 1 ,or rifapentine 1800mg·day−1 46 Multi-arm, multi-stage clinical trial NCT05401071 PredictTB 2 Yes Multicountry 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 2 months of isoniazid and rifampicin 4 Strategy trial only participants with moderate disease are randomised NCT02821832 PRESCIENT 2 Yes Multicountry Bedaquiline, clofazimine, delamanid, and pyrazinamide 2 NCT05556746 Continued https://doi.org/10.1183/2312508X.10024622 131 TREATMENT OF DS-TB AND DR-TB |C. LANGE ET AL.